Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies - a systematic review
The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the rapid and successful development of vaccines to help mitigate the effect of the coronavirus disease 2019 (COVID-19) and circulation of the virus. Preclinical vaccine trials provide a wealth of information about the presence and persistence of virus in different anatomical sites. We systematically reviewed all available preclinical SARS-CoV-2 candidate vaccine studies where non-human primates were challenged after vaccination. We found marked heterogeneity in experimental design between the studies. Most of the tested vaccines, only triggered a low or moderate reduction of viral RNA in the upper respiratory tract; We need to consider that most SARS-CoV-2 vaccines that protect against disease might not fully protect against infectiousness and vaccinated individuals might still contribute to SARS-CoV-2 transmission. Careful assessment of secondary attack rates from vaccinated individuals is warranted. Standardization in design and reporting of preclinical trials is necessary.
| Main Authors: | , , , , |
|---|---|
| Format: | Working paper biblioteca |
| Language: | English |
| Published: |
OSF Preprints
|
| Subjects: | Life Science, |
| Online Access: | https://research.wur.nl/en/publications/assessment-of-the-efficacy-of-sars-cov-2-vaccines-in-non-human-pr |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the rapid and successful development of vaccines to help mitigate the effect of the coronavirus disease 2019 (COVID-19) and circulation of the virus. Preclinical vaccine trials provide a wealth of information about the presence and persistence of virus in different anatomical sites. We systematically reviewed all available preclinical SARS-CoV-2 candidate vaccine studies where non-human primates were challenged after vaccination. We found marked heterogeneity in experimental design between the studies. Most of the tested vaccines, only triggered a low or moderate reduction of viral RNA in the upper respiratory tract; We need to consider that most SARS-CoV-2 vaccines that protect against disease might not fully protect against infectiousness and vaccinated individuals might still contribute to SARS-CoV-2 transmission. Careful assessment of secondary attack rates from vaccinated individuals is warranted. Standardization in design and reporting of preclinical trials is necessary. |
|---|